Pacer Advisors, Inc. Intellia Therapeutics, Inc. Transaction History

Pacer Advisors, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$20.02 - $27.22 $4,824 - $6,560	-241 Reduced 16.89%	1,186 $26,000
Q1 2024 May 10, 2024	BUY	$23.82 - $32.8 $33,991 - $46,805	1,427 New	1,427 $39,000
Q2 2021 Jul 21, 2021	SELL	$60.88 - $161.91 $72,386 - $192,510	-1,189 Closed	0 $0
Q1 2021 Apr 05, 2021	SELL	$46.59 - $83.68 $59,728 - $107,277	-1,282 Reduced 51.88%	1,189 $95,000
Q4 2020 Jan 20, 2021	SELL	$18.83 - $63.53 $3,916 - $13,214	-208 Reduced 7.76%	2,471 $134,000
Q3 2020 Oct 19, 2020	BUY	$17.47 - $24.93 $46,802 - $66,787	2,679 New	2,679 $53,000
Q4 2018 Feb 13, 2019	SELL	$11.39 - $27.13 $86,085 - $205,048	-7,558 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$25.78 - $32.6 $194,845 - $246,390	7,558 New	7,558 $216,000

314

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $867M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Pacer Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Pacer Advisors, Inc. with notifications on news.